Transcatheter aortic valve implantation (TAVI) is a novel therapeutic option for patients with severe symptomatic aortic stenosis (AS) at excessive or high surgical risk for conventional surgical aortic valve replacement. First commercialised in Europe in 2007, TAVI growth has been exponential among some Western European nations, though recent evidence suggests heterogeneous adoption of this new and expensive therapy. Herein, we review the evidence describing the utilisation of TAVI in Western Europe.
Darren Mylotte - Department of Interventional Cardiology, McGill University Health Centre, Montreal, Quebec, Canada
Ruben LJ Osnabrugge - Erasmus University Medical Center, Rotterdam, The Netherlands
Giuseppe Martucci - Department of Interventional Cardiology, McGill University Health Centre, Montreal, Quebec, Canada
Ruediger Lange - German Heart Centre, Munich, Germany
Arie Pieter Kappetein - Erasmus University Medical Center, Rotterdam, The Netherlands
Nicolo Piazza - Department of Interventional Cardiology, McGill University Health Centre, Montreal, Quebec, Canada
